Cosmos Health Inc. has expanded its contract manufacturing capabilities through its wholly-owned subsidiary Cana Laboratories, which inaugurated a new ACG capsule-filling line and secured a five-year agreement with Provident Pharmaceuticals. The deal involves the production of 385,000 units of CERTORUN (sertraline hydrochloride), an antidepressant in the selective serotonin reuptake inhibitor (SSRI) class used to treat depression, anxiety, and related disorders. This strategic move is designed to generate high-margin, recurring revenue and strengthen the company's order book across multiple therapeutic areas.

Under the terms of the agreement, Cana Laboratories will manufacture an annual volume of 77,000 units. The product will be produced in two specific strengths: CERTORUN Caps 50mg/cap and CERTORUN Caps 100mg/cap, both packaged in blister formats of 3x10 (BTx30). Production will be executed on Cana's newly installed ACG capsule-filling line, a development that marks the company's ongoing investment in upgrading and modernizing its European GMP-certified infrastructure.

Contract Details and Production Capacity

The new contract builds upon an existing relationship between Cana and Provident, which previously included manufacturing agreements for products such as DE3-SOLE, MIOREL, CALCIFOLIN, and DEXA-DOSE. The integration of the ACG capsule-filling machine is intended to enhance solid-dosage production capacity and support the fulfillment of this new order.

Strategic Growth and Revenue Impact

Greg Siokas, CEO of Cosmos Health, emphasized that the contract manufacturing division is a core pillar of the company's long-term growth strategy. He stated that multi-year agreements with established partners like Provident build a stable, predictable revenue base while diversifying the order book across categories ranging from central nervous system to musculoskeletal and anti-inflammatory. The continued modernization of manufacturing infrastructure is aimed at securing new contracts and accelerating the growth of this segment.

Cosmos Health Inc. announced on June 08, 2026, that its wholly owned subsidiary, Cana Laboratories S.A., has acquired the international patent application WO2025108566A1 from Cloudpharm P.C. This acquisition supports the development of next-generation pharmaceutical, nutraceutical, OTC, and specialized healthcare products. The company is expanding its nanotechnology investment initiatives, leveraging Cana Laboratories' European GMP-certified manufacturing capabilities to drive long-term shareholder value.

Following the transfer, Cana Laboratories has initiated the process of pursuing patent protection at both national and regional levels in key international markets. The underlying technology originated from research activities combining early-stage discovery methodologies with advanced pharmaceutical development approaches. This move aligns with Cosmos Health's broader strategy of expanding its intellectual property portfolio and strengthening vertical integration.

In parallel with the patent acquisition, Cana Laboratories announced plans to expand investments in nanotechnology-based product development platforms. The company intends to integrate the patented technology with additional nanotechnology applications. This integration aims to create a foundation for the future development of differentiated, high-margin healthcare products using Cana Laboratories' European GMP-licensed and EMA-certified platform.

Greg Siokas, CEO of Cosmos Health, stated that the acquisition strengthens the company's transition from AI-enabled discovery to proprietary product development and commercialization. He emphasized that combining intellectual property, advanced formulation technologies, nanotechnology expertise, and manufacturing infrastructure builds a scalable innovation platform.

Patent and IP Details